WEREWOLF ®, the WEREWOLF logo, PREDATOR ®, INDUKINE ™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have a $8.00 ...

Werewolf Therapeutics provided a business update, announcing progress in their clinical trials for WTX-124, a conditionally activated therapeutic for cutaneous melanoma, with full enrollment in ...

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated ...

Werewolf Therapeutics has a 52 week low of $1.12 and a 52 week high of $7.17. The firm’s 50-day simple moving average is $1.41 and its 200 day simple moving average is $1.87.

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the ...

Werewolf Therapeutics, Inc. WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical ...

– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first ...